Skip navigation
Watchlist Sponsored By :


Current DateTime: 11:26:43 15 Nov 2009
LinksList Documentid: 24355697

FEATURED QUIZZES


Current DateTime: 11:26:43 15 Nov 2009
LinksList Documentid: 33793611
  • The Billionaire BFF's

      Philanthropists. Bridge partners. Hockey players. Which responses are based on facts from Buffett's and Gates' real lives?

  • The Many Myths of Coca-Cola

      Can you tell which statements are true, and which ones are just rumors?

  • Think You Understand Markets?

      We've selected some questions from the Financial Industry Regulatory Authority's test of investor knowledge. See how you do ...


Current DateTime: 11:26:43 15 Nov 2009
LinksList Documentid: 24890560
  • Winterizing Your Portfolio

      If 2009 was the winter of our discontent, will 2010 be a winter wonderland for investors? A lot depends on the recovery—or lack thereof.

  • Investor's Guide to Real Estate

      Some even say the long-awaited recovery is here. Regardless, buyers and sellers alike can profit from our guide.

  • Alternative Investing

      Stocks and bonds? Sure. But it's a big world out there for investors.

powered by digg
Wyeth Results Up on Growing Vaccine Revenues
Companies:Wyeth
By: Reuters | 19 Apr 2007 | 09:29 AM ET
Text Size

Wyeth [WYE  Loading...      ()   ] said quarterly earnings rose a better-than-expected 12% on strong sales of its vaccine against childhood infections, and reported positive trial results for its most important experimental drug.

The trial data shows low doses of Pristiq were effective against both depression and hot flashes and caused less nausea than seen in prior studies of higher doses. Although the new data will take more time for regulators to analyze, it could bolster prospects for its eventual approval and commercial success.

Pristiq is now awaiting U.S. approval as a treatment for both conditions. But Wyeth and investors have been concerned about a high incidence of nausea seen among patients who took the drug in earlier trials to treat depression and hot flashes.

Wyeth expects the FDA to extend its hot-flashes review by three months to examine data from the low-dose trials and expects the agency to decide by the first quarter of 2008 whether to approve Pristiq as a treatment for depression.

The company earned $1.25 billion, or 92 cents a share, compared with $1.12 billion, or 82 cents a share, in the year-ago period.

Excluding special items, Wyeth earned 94 cents a share. Analysts on average expected 87 cents a share, according to Reuters Estimates.

Total revenue in the period increased 11% to $5.4 billion for the 2007 first quarter. Prevnar, Wyeth's vaccine for infections, was the biggest gainer by sales in the quarter,
jumping 43% to $617 million.

Antidepressant Effexor continued to be Wyeth's top seller at $891 million in the period, but sales slid 6% from a year earlier due to increased competition.

Copyright 2009 Reuters. Click for restrictions.
Tools:
Print EmailAdd This share icon
  • digg share

CNBC HIGHLIGHTS

  • Warren Buffett and Bill Gates spoke to Columbia students, and Buffett made the students a startling offer.
  • Brian L. Roberts
  • For the chief of cable company Comcast, growth has been about making deals – generally very large deals.
  • Some companies may start using insurance to shift carbon risk from their balance sheets to maybe... yours?
  • The president and founder of Genesis Today wants to improve America’s health, and thinks Wal-Mart can help.
  • Switzerland's privacy watchdog is taking legal action to force Google to make changes to its Street View service.
  • A wealthy, distracted Texas driver crashed his million-dollar Bugatti Veyron sports car into a salt marsh, say police.
ADD COMMENTS
Remaining characters


Current DateTime: 01:03:48 15 Nov 2009
LinksList Documentid: 29778428

Current DateTime: 01:05:48 15 Nov 2009
LinksList Documentid: 29779196

Current DateTime: 01:02:04 15 Nov 2009
LinksList Documentid: 29779199

Current DateTime: 01:02:04 15 Nov 2009
LinksList Documentid: 29779198
  Data is a real-time snapshot  *Data is delayed at least 15 minutes
Global Business and Financial News, Stock Quotes, and Market Data and Analysis

© 2009 CNBC, Inc.  All Rights Reserved.
A Division of NBC Universal
Thomson ReutersThomson Reuters